Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment

BJU International

Volumn 88, Issue 6, 2001, Pages 602-610

  Saint, F ^a   Patard, J J ^a   Groux Muscatelli, B ^a   Lefrere Belda, M A ^a   Gil Diez De Medina, S ^a   Abbou, C C ^a   Chopin, D K ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

BCG; Superficial bladder cancer; Tumour rejection mechanisms

Indexed keywords

BCG VACCINE; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER WALL; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HELPER CELL; HOST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; KIDNEY DONOR; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR REJECTION; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; BIOPSY; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM STAGING; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0035731053     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02394.x     Document Type: Article

References (35)

1. Dendritic cells: From ontogenetic orphans to myelomonocytic descendants
2. In vivo description of dendritic cells in human renal cell carcinoma
3. Dendritic cell based immunotherapy of renal cell carcinoma
4. Tumor antigens recognized by T lymphocytes
5. Physiology and pathology of dendritic cells
6. Intracavity Bacillus Calmette Guerin in the treatment of superficial bladder tumors
7. Experience with intravesical Bacillus Calmette Guerin therapy of superficial bladder tumors
8. A Bacillus Calmette-Guérin in superficial transitional cell carcinoma
9. Local immune response after intravesical BCG treatment of carcinoma in situ
10. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
11. Urinary cytokines during intravesical Bacillus Calmette Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
12. Evaluation of local immune response after intravesical Bacille Calmette-Guérin treatment for superficial bladder cancer
13. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cell phenomenon
14. Immunoenzymatic labeling of monoclonal antibodies using immune complex of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes)
15. Immunohistochemical identification of lymphocyte subset and macrophages in normal human urothelium using monoclonal antibodies
16. Transitional cell carcinoma expresses high levels of Fas ligand in vivo
17. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas
18. The frequency of major histocompatibility complex antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation
19. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors
20. Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall
21. Requirement of thymus dependent immune response for BCG-mediated antitumor activity
22. Activation of human dendritic cells by Bacillus Calmette-Guérin
23. The persistence of Bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer
24. Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells
25. Local immune response after intravesical interferon gamma in superficial bladder cancer
26. Intercellular adhesion molecule-1 expression by bladder cancer cells: Functional effects
27. Co-expression of B7-BB1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response
28. Specific activation of human peripheral blood γ/δ+ T lymphocytes by sonicated antigens of mycobacterium tuberculosis: Role in vitro in killing human bladder carcinoma cell lines
29. Differential production of interferon-γ and interleukin-4 in response to Th1- and Th2-stimulating pathogens by γδ T cells in vivo
30. Bacille Calmette-Guérin vaccination enhances human γδ T cell responsiveness to mycobacteria suggestive of a memory-like phenotype
31. Human monocytes, lymphocytes and granulocytes antibody-dependent cell mediated cytotoxicity toward tumour cells
32. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients
33. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of Bacillus Calmette-Guérin during intravesical treatment of superficial bladder cancer
34. Effects of local Bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of bladder wall
35. Urinary interleukin-2 monitoring during prolonged Bacillus Calmette-Guérin treatment: Can it predict the optimal number of instillations?